Abstract
Background Despite the ongoing opioid epidemic, the mortality risk of opioid initiation in patients with dementia or mild cognitive impairment (MCI) remains understudied despite their vulnerability. This study evaluates mortality risks associated with opioid use in patients diagnosed with dementia or MCI by comparing outcomes between new and consistent users.
Methods We conducted a retrospective cohort study using data from Northern California academic healthcare system (2015/01/01-2024/07/31), including 27,757 patients aged 50–100 with dementia or MCI. Of these, 14,105 received opioids after diagnosis and were classified as new (opioid-naïve; n=9444) or consistent (non-naïve; n=4663) users. Cox regression assessed 14-day mortality risk. Aalen’s additive model examined time-varying impact. Causes of death were extracted from clinical notes using GPT-3·5-Turbo. Findings were validated in community healthcare system cohort (n=207,873) across western U.S. states (2015/01/01-2023/05/31).
Findings In the primary cohort, 4.1% (572/14105) of patients died within 14 days of opioid exposure. New users had a significantly higher 14-day mortality risk than consistent users (adjusted hazard ratio [aHR], 2·00 [1·59–2·52]; P<0·0001). The validation cohort had a 14-day mortality rate of 6·2% (7022/113343) with a smaller difference between new (n=77,204) and consistent (n=36,194) users (aHR 1·20 [1·13–1·27]; P<0·0001). In both cohorts, elevated risk stabilized after day 30. In the primary cohort, respiratory conditions, particularly pneumonia, were more prevalent among new users who died early.
Interpretation Opioid initiation in these patients is associated with increased short-term mortality in new users, underscoring the need for cautious initiation and close monitoring during the first month.
Funding NIH
Competing Interest Statement
YH, JMH, JEB, and THB declare no conflict of interest. JJH has received grant funding from Pfizer and Novartis and contract funding from Janssen, Bristol Myers Squibb, and Gilead for research unrelated to this study.
Funding Statement
This project was supported by grant number R01HS024096 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Stanford University Institutional Review Board (Protocol 47644) and Providence St. Joseph Health Institutional Review Board (Protocol STUDY2024000402).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos